TMEp-CI-M platform achieves >20 months disease-free survival in refractory SCLC with brainstem metastasis
Background
Brainstem metastasis from small-cell lung cancer (SCLC) is exceedingly rare and carries a dismal prognosis, often due to the aggressive nature of SCLC and its propensity for early metastasis. Current standard-of-care treatments, including chemotherapy and radiation, frequently fall short in achieving durable responses, especially in advanced or refractory cases. Immunotherapy with checkpoint inhibitors has shown some promise but often faces resistance in immunologically "cold" tumors like SCLC. This study explores a multi-modal platform designed to overcome this resistance by targeting the tumor microenvironment (TME), immune checkpoints, and the microbiome.
Study Design
This case report details a 60-year-old male with PD-L1-negative extensive-stage SCLC and brainstem metastasis. The patient received the TMEp-CI-M platform, which involved sequential phases. The TMEp phase integrated stereotactic body radiotherapy (SBRT), low-dose etoposide, and anlotinib. This was followed by the CI phase, which utilized the programmed death 1 (PD-1) / cytotoxic T lymphocyte antigen 4 (CTLA-4) bispecific antibody cadonilimab, concurrent with probiotic supplementation for microbiome modulation. The patient underwent a total of 6 treatment cycles.
Results
The TMEp-CI-M platform demonstrated a profound and rapid response in the patient. The pro-gastrin-releasing peptide (ProGRP) level, a key biomarker for SCLC, normalized dramatically after the first cycle, dropping from 1803 pg/mL to 23.71 pg/mL. This significant reduction indicated a robust initial response to the treatment regimen. At the time of this report, the patient remains with no evidence of disease (NED) for more than 20 months following treatment initiation, signifying a durable complete response. > The patient experienced only one adverse event: Grade 1 hypothyroidism, indicating a favorable safety profile for this intensive multi-modal therapy. This sustained remission in a highly refractory case with brainstem metastasis highlights the potential efficacy of the TMEp-CI-M approach.
Key Findings
- TMEp-CI-M platform achieved a complete response in a patient with refractory ES-SCLC and brainstem metastasis.
- Patient maintained no evidence of disease (NED) for over 20 months post-treatment.
- Pro-gastrin-releasing peptide (
ProGRP) normalized from 1803 pg/mL to 23.71 pg/mL after 1 cycle. - Only Grade 1 hypothyroidism was reported as an adverse event.
Why It Matters
This case report offers compelling evidence that the TMEp-CI-M platform may enhance immunotherapy efficacy in highly challenging cases of extensive-stage SCLC, particularly those with rare and aggressive brainstem metastases. For peptide users and clinicians, this suggests a novel strategy for overcoming resistance in "cold" tumors by combining TME priming, dual checkpoint inhibition, and microbiome modulation. This multi-pronged approach could pave the way for more durable responses in SCLC patients who currently have very limited therapeutic options. While a single case, it provides a blueprint for future clinical trials, indicating that a usable protocol combining these elements might be feasible, though large-scale validation is still needed.
sclc
brainstem-metastasis
tmep-ci-m
immunotherapy
cadonilimab
case-report